PDT Partners’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

PDT Partners’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,866	Closed	-$61K	–	1224
2022 Q1	$61K	Buy	+10,866	New	+$44.8K	0.01%	897
2021 Q3	–	Sell	-37,200	Closed	-$245K	–	983
2021 Q2	$245K	Sell	37,200 -9,466	-20%	-$65.3K	0.02%	658
2021 Q1	$342K	Sell	46,666 -13,451	-22%	-$116K	0.02%	589
2020 Q4	$347K	Sell	60,117 -1,722	-3%	-$9.86K	0.02%	518
2020 Q3	$367K	Buy	+61,839	New	+$306K	0.02%	511

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

PDT Partners's AVEO Position: Q2 2022 in Review

PDT Partners sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2022, closing a stake of 10,866 shares — an estimated $61K sold.

PDT Partners first reported a position in AVEO in Q3 2020 and held it in 5 quarters. The position peaked at $367K in Q3 2020. 56 funds tracked by Wall St. Rank hold AVEO as of Q2 2022.

PDT Partners reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
PDT Partners sold 10,866 AVEO Pharmaceuticals, Inc. shares in Q2 2022, an estimated $61K.
PDT Partners first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2020 and held it in 5 quarters.
PDT Partners's AVEO Pharmaceuticals, Inc. position peaked at $367K in Q3 2020.
56 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.